Cytokinetics to Present at the Banc of America Securities Specialty Pharmaceuticals Conference

South San Francisco, CA - July 23, 2004

Cytokinetics, Inc. (Nasdaq: CYTK) announced today that Robert I. Blum, Executive Vice President, Finance and Corporate Development and Chief Financial Officer, is scheduled to present a corporate update at the Banc of America Securities Specialty Pharmaceuticals Conference. The presentation is scheduled to occur on Friday, July 30, 2004 at 8:45 am EDT at the Southampton Inn in Southampton, NY. Interested parties may access the live audio webcast of the presentation and replay it by visiting the Cytokinetics website at www.cytokinetics.com. The webcast replay of the presentation will be archived on the Audio Presentations page in the Investors Center section of Cytokinetics’ website until August 6, 2004.

About Cytokinetics


This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to advancing clinical development of SB-715992, SB-743921 and progressing Cytokinetics’ research programs and statements regarding the potential benefits of the Cytokinetics' drug candidates and the enabling capabilities of its proprietary technologies. Such statements are based on management’s current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company’s drug candidates that could slow or prevent clinical development, product approval or market acceptance (including the risk that uncertainty of patent protection for the Company’s intellectual property or trade secrets, the Company’s ability to obtain additional financing if necessary and unanticipated research and development and other costs). For further information regarding these and other risks related to the Company’s business, investors should consult the Company’s filings with the Securities and Exchange Commission.